Literature DB >> 16322235

Platelet-derived growth factor-induced p42/44 mitogen-activated protein kinase activation and cellular growth is mediated by reactive oxygen species in the absence of TSC2/tuberin.

Geraldine A Finlay1, Victor J Thannickal, Barry L Fanburg, David J Kwiatkowski.   

Abstract

Tuberous sclerosis complex (TSC) is a genetic disorder caused by inactivating mutations in the TSC1 or TSC2 genes, which encode hamartin and tuberin, respectively. TSC is characterized by multiple tumors of the brain, kidney, heart, and skin. Tuberin and hamartin inhibit signaling by the mammalian target of rapamycin (mTOR) but there are limited studies of their involvement in other pathways controlling cell growth. Using ELT-3 cells, which are Eker rat-derived smooth muscle cells, we show that ELT-3 cells expressing tuberin (TSC2+/+) respond to platelet-derived growth factor (PDGF) stimulation by activating the classic mitogen-activated protein (MAP)/extracellular signal-regulated kinase kinase (MEK)-1-dependent phosphorylation of p42/44 MAP kinase (MAPK) with nuclear translocation of phosphorylated p42/44 MAPK. In contrast, in tuberin-deficient ELT-3 cells (TSC2-/-), PDGF stimulation results in MEK-1-independent p42/44 MAPK phosphorylation with reduced nuclear localization of phosphorylated p42/44 MAPK. Moreover, in TSC2-/- cells but not in TSC2+/+ cells, cellular growth and activation of p42/44 MAPK by PDGF requires the reactive oxygen species intermediate, superoxide anion (O2*-). Both baseline and PDGF-induced O2*- levels were significantly higher in TSC2-/- cells and were reduced by treatment with rapamycin and inhibitors of mitochondrial electron transport. Furthermore, the exogenous production of O2*- by the redox cycling compound menadione induced MEK-1-independent cellular growth and p42/44 MAPK phosphorylation in TSC2-/- cells but not in TSC2+/+ cells. Together, our data suggest that loss of tuberin, which causes mTOR activation, leads to a novel cellular growth-promoting pathway involving mitochondrial oxidant-dependent p42/44 MAPK activation and mitogenic growth responses to PDGF.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16322235     DOI: 10.1158/0008-5472.CAN-05-1394

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

1.  Tuberous sclerosis complex activity is required to control neuronal stress responses in an mTOR-dependent manner.

Authors:  Alessia Di Nardo; Ioannis Kramvis; Namjik Cho; Abbey Sadowski; Lynsey Meikle; David J Kwiatkowski; Mustafa Sahin
Journal:  J Neurosci       Date:  2009-05-06       Impact factor: 6.167

2.  High-throughput drug screen identifies chelerythrine as a selective inducer of death in a TSC2-null setting.

Authors:  Doug Medvetz; Yang Sun; Chenggang Li; Damir Khabibullin; Murugabaskar Balan; Andrey Parkhitko; Carmen Priolo; John M Asara; Soumitro Pal; Jane Yu; Elizabeth P Henske
Journal:  Mol Cancer Res       Date:  2014-09-03       Impact factor: 5.852

3.  Proapoptotic protein Bim attenuates estrogen-enhanced survival in lymphangioleiomyomatosis.

Authors:  Chenggang Li; Na Li; Xiaolei Liu; Erik Y Zhang; Yang Sun; Kouhei Masuda; Jing Li; Julia Sun; Tasha Morrison; Xiangke Li; Yuanguang Chen; Jiang Wang; Nagla A Karim; Yi Zhang; John Blenis; Mauricio J Reginato; Elizabeth P Henske; Jane J Yu
Journal:  JCI Insight       Date:  2016-11-17

4.  PYK2 signaling is required for PDGF-dependent vascular smooth muscle cell proliferation.

Authors:  Jessica Perez; Rebecca A Torres; Petra Rocic; Mary J Cismowski; David S Weber; Victor M Darley-Usmar; Pamela A Lucchesi
Journal:  Am J Physiol Cell Physiol       Date:  2011-03-30       Impact factor: 4.249

5.  Regulable neural progenitor-specific Tsc1 loss yields giant cells with organellar dysfunction in a model of tuberous sclerosis complex.

Authors:  June Goto; Delia M Talos; Peter Klein; Wei Qin; Yvonne I Chekaluk; Stefanie Anderl; Izabela A Malinowska; Alessia Di Nardo; Roderick T Bronson; Jennifer A Chan; Harry V Vinters; Steven G Kernie; Frances E Jensen; Mustafa Sahin; David J Kwiatkowski
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-24       Impact factor: 11.205

6.  mTORC1-Driven Tumor Cells Are Highly Sensitive to Therapeutic Targeting by Antagonists of Oxidative Stress.

Authors:  Jing Li; Sejeong Shin; Yang Sun; Sang-Oh Yoon; Chenggang Li; Erik Zhang; Jane Yu; Jianming Zhang; John Blenis
Journal:  Cancer Res       Date:  2016-05-17       Impact factor: 12.701

7.  Autophagy-dependent metabolic reprogramming sensitizes TSC2-deficient cells to the antimetabolite 6-aminonicotinamide.

Authors:  Andrey A Parkhitko; Carmen Priolo; Jonathan L Coloff; Jihye Yun; Julia J Wu; Kenji Mizumura; Wenping Xu; Izabela A Malinowska; Jane Yu; David J Kwiatkowski; Jason W Locasale; John M Asara; Augustine M K Choi; Toren Finkel; Elizabeth P Henske
Journal:  Mol Cancer Res       Date:  2013-12-02       Impact factor: 5.852

8.  AMP-activated protein kinase signaling results in cytoplasmic sequestration of p27.

Authors:  John D Short; Kevin D Houston; Ruhee Dere; Sheng-Li Cai; Jinhee Kim; Charles L Johnson; Russell R Broaddus; Jianjun Shen; Susie Miyamoto; Fuyuhiko Tamanoi; David Kwiatkowski; Gordon B Mills; Cheryl Lyn Walker
Journal:  Cancer Res       Date:  2008-08-15       Impact factor: 12.701

9.  Melatonin represses oxidative stress-induced activation of the MAP kinase and mTOR signaling pathways in H4IIE hepatoma cells through inhibition of Ras.

Authors:  Scot R Kimball; Ahmed Abbas; Leonard S Jefferson
Journal:  J Pineal Res       Date:  2008-05       Impact factor: 13.007

10.  Rapamycin-resistant poly (ADP-ribose) polymerase-1 overexpression is a potential therapeutic target in lymphangioleiomyomatosis.

Authors:  Yang Sun; Dana Gallacchi; Erik Y Zhang; Samuel B Reynolds; Lauren Robinson; Izabela A Malinowska; Terry T Chiou; Ana M Pereira; Chenggang Li; David J Kwiatkowski; Po-Shun Lee; Jane J Yu
Journal:  Am J Respir Cell Mol Biol       Date:  2014-12       Impact factor: 6.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.